Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Hochhaus A, et al. Among authors: druker b. Blood. 2008 Feb 1;111(3):1039-43. doi: 10.1182/blood-2007-07-103523. Epub 2007 Oct 11. Blood. 2008. PMID: 17932248 Free article. Clinical Trial.
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Larson RA, et al. Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6. Blood. 2008. PMID: 18256322 Free article. Clinical Trial.
Chronic myeloid leukemia: current treatment options.
Goldman JM, Druker BJ. Goldman JM, et al. Among authors: druker bj. Blood. 2001 Oct 1;98(7):2039-42. doi: 10.1182/blood.v98.7.2039. Blood. 2001. PMID: 11567987 Free article.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group. Kantarjian H, et al. Among authors: druker b. N Engl J Med. 2002 Feb 28;346(9):645-52. doi: 10.1056/NEJMoa011573. N Engl J Med. 2002. PMID: 11870241 Free article. Clinical Trial.
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. Guilhot F, et al. Among authors: druker b. Haematologica. 2009 Dec;94(12):1669-75. doi: 10.3324/haematol.2009.010629. Epub 2009 Jul 31. Haematologica. 2009. PMID: 19648168 Free PMC article. Clinical Trial.
Chronic myelogenous leukemia.
Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Druker BJ, et al. Hematology Am Soc Hematol Educ Program. 2001:87-112. doi: 10.1182/asheducation-2001.1.87. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722980 Review.
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Hochhaus A, et al. Among authors: druker bj. Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741. Leukemia. 2002. PMID: 12399961 Clinical Trial.
511 results